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Mouse strains BIO, BIO.RIII, RIIIS/J and the FI and backcross progeny arising from them were tested for 
susceptibility to porcine type II collagen-induced arthritis (PII-CIA). The clinically severe arthritis of rapid 
onset that is characteristic of PH-immunized B 10.RIII mice developed predominantly in hybrid offspring that 
had inherited at least one copy of wild type T cell receptor (TCR) genes (V/Jb genotype) from the BIO or 
BIO.RIII parent. The results indicate that, in the development of PII-CIA, mice expressing the H-2,/r haplo- 
lype preferentially utilize TCR V/} genes that are normally encoded within the TCR V/3 genomic deletion 
region of RIIIS mice CV/3‘). After aggressive immunization with PII, the use of alternative TCR V/? genes, 
encoded outside of the RIIIS deletion region, produced a high IgG antibody response that was cross-reactive 
with mouse type II collagen (Mil) and equivalent to that of BIO.RIII mice, but only a very mild, late onset 
arthritis of 56% (27/48) incidence in RIIIS male mice and 28% (10/35) incidence in RIIIS female mice. In 
comparison, BIO.RIII mice routinely developed early onset of PII-CIA of significantly higher incidence 
(100%; p<0.005) and four-fold greater severity, even after milder immunization protocols. The data are com­
patible with the proposal that the clinically weak CIA response of RIIIs mice may be primarily antibody 
driven while the severe CIA of BIO.RIII mice reflects the added inflammatory effects of collagen-reactive 
effector-T cells in the joint. The apparent concordance of TCR V/3 utilization in the murine T cell response to 
MAM (a superantigen produced by M. arthritidis), to Mls-\J (a retroviral superantigen), and to homologous 
type II collagen is discussed.
KEY WORDS: Arthritis, collagen, T cell receptors, mice, superantigens.
ABBREVIATIONS: Mis, minor lymphocyte stimulating antigen; TCR, antigen specific T cell receptor; H-2, 
mouse major histocompatibility complex; Ab, antibody; PII, BII, CII, Mil, native type 
II collagen of porcine, bovine, chick, mouse origin; CIA, collagen-induced arthritis;
MAM, Mycoplasma arthritidis superantigen; V/3C, genomic deletion mutation of RIIIS 
lacking TCR V/3 allotypes 9, 11, 12, 13, 8, 5, 6, 15, 17; V/}b, wild-type TCR genotype;
V /3 \genomic deletion mutation of SWR lacking V/J9, II, 12, 13,8,5.
INTRODUCTION
Collagen-induced arthritis (CIA) is an established 
rodent model of experimentally-induced, autoimmune 
joint disease1,2. CIA is initiated by immunization with 
homologous or heterologous, native type II collagen, a 
major component of articular cartilage. Both cellular 
and humoral immunity to autologous type II collagen 
are necessary for rapid onset and severe arthritis3. CIA 
thus provides insight into the immunogenetics and 
immunobiology of an autoimmune process that is 
commonly found among patients with several of the 
rheumatic diseases.
In mice, CIA is under multiple gene control and 
linkages to MHC-encoded class II molecules (H-2A
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gene products) and to non-MHC encoded T cell 
antigen receptor (TCR) molecules have been found4' 9. 
For example, BIO.RIII (H-2r) mice readily develop a 
severe arthritis o f rapid onset in response to immuniz­
ation with bovine (BII) and porcine (PII) type II col- 
lagens while mice of the MHC-congenic BIO (H-2b) 
strain do not. However, RIIIS mice, which also 
express the CIA-susceptible H-2r haplotype, are rela­
tively resistant to BH-induced CIA. RIIIS mice have a 
genomic deletion of 70% of the genes that encode the 
variable region domains of the TCR beta chains, sug­
gesting that the missing TCR V /3 chains are important 
in the development of CIA in H-2r mice'0,11. Alterna­
tively, RIIIS mice likely differ from BIO.RIII mice at 
multiple non-H-2 loci, in addition to the TCR V/3 
genes. Thus, theoretically, the different clinical 
expression of collagen autoimmunity in these two 
strains could be due to as yet unidentified gene prod­
ucts and not to differences in TCR genotypes. Also, 
PII, which differs antigenically from BII, is a potent
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arthritogen for BlO.RIII mice but its effect in RIIIS 
mice has not been systematically examined.
To further investigate these questions, we carried 
out a classical, gene-segregation analysis among the 
hybrid offspring of matings between BIO, RIIIS and 
BlO.RIII. Over 200 parental, FI and backcross pro­
geny were immunized with PII and evaluated for 
clinical responses, levels of IgG antibody to homolo­
gous mouse type II collagen (M il) and TCR V/? 
phenotypes.
RIIIS/J, C57BL10 (BIO), and BlO.RIII were orig­
inally purchased from Jackson Laboratory (Bar 
Harbor, ME). FI and backcross progeny were bred at 
the Animal Resources Building, University of Utah or 
the Mayo Immunogenetic Mouse Colony. Mice were 
eight to 12 wks of age at the time of immunization 
with type II collagen. BIO (H-2b) and BlO.RIII (H-2r) 
mice possess a wild type (non-deleted) TCR genotype 
designated TCR V /Ib. RIIIS (H-2r) mice are genomic 
deletion mutants (TCR V/Jc) that have lost the DNA 
segment encoding TCR V/3 domains 5, 9, 11, 12, 13,
8.1, 8.2, 8.3, 6, 15, 17.
Serotyping of hybrid progeny for H-2r and H-2b were 
by conventional polyvinylpyrrolidone hemagglutin­
ation techniques with appropriate antisera at 4 wks of
Peripheral blood was obtained by tail bleeds at 6 wks 
of age and lymphocytes were purified by isopaque 
gradient centrifugation. T-cell subsets were identified 
by dual fluorescence flow cytometry on a FACS IV 
Flow Cytometer (Becton Dickinson, Mountain View, 
CA) using dye conjugated monoclonal antibodies as 
previously detailed12. PBS containing 1% B S A  and
0.05% sodium azide was used for all cell washes and 
antibody dilutions. FACS analysis results were dis­
played as two-color contour diagrams from which the 
percentage of T-cells (Thyl+) co-expressing Vj36+ or 
VJ38+ TCR was calculated.
The TCR V/J genotype was determined by analysis 
of peripheral lymphocytes for T cells expressing 
either V j36+ or V/J8.2+ TCR molecules, both of which 
are encoded within the DNA segment that is deleted in 
the RIIIS mouse. V j36+ TCR-bearing T-cells were 
detected with the rat anti-mouse monoclonal antibody, 
44-22-I3 a gift of Dr Hans Hengartner, Zurich, Switz­
erland, and a Biotin or FITC conjugated F(ab)2 fra9 
ment o f mouse anti-rat IgG second antibody (Accurate 
Chemical Company, Westbury, NY). V/J8.2+ TCR 
bearing T-cells were detected with the mouse anti­
mouse monoclonal F23.2, a gift from Dr P. Marrack14 
The second antibody was goat-anti-mouse IgG, pc 
specific and appropriately conjugated with either 
FITC or biotin (Accurate Chem. Co.). Total mature T- 
cells were stained with biotinylated anti-Thy 1.2, a 
pan T-cell marker (ATCC, Rockville, MD) plus Strep- 
tavidin phycoerythrin (TAGO, San Francisco, CA).
Collagens
Porcine type II collagen (PII) was solubilized from 
articular cartilage by pepsin digestion after extraction 
of proteoglycans into 4M Guanidine hydrochloride. 
PII was further purified by DEAE chromatography 
and by repeated fractional precipitation with NaCl and 
low ionic strength phosphate buffer. The final prep­
aration was free of other collagen types by PAGE 
analysis and of proteoglycans by uronic acid analysis. 
A detailed procedure has been described15. Mouse 
type II collagen (M il) was prepared from sternal and 
ear cartilage by identical protocols.
CIA: Induction and assessment
PII was dissolved overnight in 0.1 N acetic acid at 
2 mg/ml and emulsified with an equal volume of CFA 
(Adjuvant Complete H37Ra; Difco). BlO.RIII, 
(BlO.RIIIxRIIIS)FlxRIIIS and FlxBlO.RIII mice 
(Table 1, Utah) received a primary immunization with 
100 fig of PII as a CFA emulsion, intradermally at the 
base o f the tail on day 0 and a booster injection of 
100 fig  PII emulsified with IFA (incomplete Freund’s 
adjuvant) at 21 d. For the study of CIA in the series of 
(BlOxRIIIS)FlxRIIIS mice (Table 2, Mayo Clinic), 
the primary injection was with 50 fig  PII in 100 //I 
CFA emulsion. In the analysis of CIA in RIIIS inbred 
mice, the protocol was modified such the primary 
injection of 100 fig  PII in CFA (M. butyricum, Difco) 
was followed by a booster injection at 21 d which util­
ized 100 fig PII emulsified in CFA rather than IFA so 
as to ensure sufficient numbers of arthritic mice for 
analysis. Mice were observed biweekly for onset and 
severity of arthritis for four months. For routine 
analysis, each paw was scored on the basis of a 0 to 
4+ system (indicative of the degree of erythema, 
swelling and joint deformity) such that the maximum 
possible score per mouse is 16+. For a comparative 
analysis of selected groups of mice, a scoring system 
was used which quantitates the severity of joint 
inflammation in detail and which involves individual 
scoring of each of the joints of the front and rear paws 
individually16. Under the detailed system the maxi­
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Table 1 Association of CIA with the wild-type TCR genotype (V;3b) among the progeny of malings between RIIIS and B10.RIII mice*
Strain or Test-Cross Sex H-2 TCR V/3 Incidence Severity Onset
bio.riii M r/r b/b 2/2 6.8±1.4 31 ±7
(BlO.RIIIXRIIIS)FlxRIIIS M r/r b/c c/c 3/9 0.6+0.4 67 ±4 3
(BlO.RIIIxRIIIS)FlxRIIIS F r/r b/c c/c 5/18 1.4±1.B 60±17
(BlO.RHIxRIIIS)FlxB 10.RIII M r/r b/c b/b 13/14 4.8+2.0 61 + 14
(BlO.RIIIxRIIIS)FlxBlO.RIII F r/r b/c b/b 11/14 3.2±2.2 77±45
•Incidence: No. Positive/No. Tested; Severity: M eaniS.D . o f maximum scores (based on arthritic mice only); 
Onset: Mean±SD, (days). TCR V /Jb=wild-type TCR V/J genome; TCR V/?C=TCR genomic deletion o f RIIIS mice.
Table 2 Association of CIA with TCR V;3b among (BlOxRIIIS)x 
RIIIS progeny and resistance to CIA among TCR Vj } dc female 
offspring*
H-2 TCR Vfi Sex Incidence (%) Onset Severity
r/b c/c M 11/17(65%) 49±13 6.5±1.9
r/b c/c F 4/18 (22%) 62±11 5.3±2.2
r/b b/c M 9/12(75%) 72± 15 5.3±1.0
r/b b/c F 8/11 (73%) 58±15 5.6±2.7
r/r c/c M 13/22 (59%) 69±20 3.8+1.6
r/r c/c F 3/13 (23%) 44±15 3.0±1.7
r/r . b/c M 17/27 (71%) 62±24 6,3±2,8
r/r b/c F 10/17 (59%) 60±18 4.4±1.7
r/r+ b/b M 6/6 (100%) 30±10 12.2±4.8
*Means±S.D. of arthritic mice only for onset (days) and severity (maximum=16). TCR 
RIIIS V/f deletion; V/Jb: wild-type TCR V/J genes. CIA in TCR V /Jc* females was 
significantly differenl from that o f  TCR V/JcA' males (p?=0.0005). Mice were 8 weeks ofd al 
the time o f primary immunization with Pll.
'Results with hybrid progeny are presented in comparison with positive control BtO.RlII 
mice (H-2,/f and TCR V /J1'*) which are 100% BIO background.
Anti-collagen antibodies
Serum samples were obtained by tail bleeds at 28 d 
after primary immunization. Relative IgG anti-col­
lagen antibody titers were quantitated using an ELISA 
assay system as previously described17 with a peroxi­
dase-conjugated, goat anti-Mouse IgG second anti­
body (Cappel). Sera were tested at 1:100, 1:400, 
1:1600 and 1:6400 dilutions. Optical density readings 
were normalized using a standard curve obtained from 
a constant, positive control sera (pooled, high titer 
B10.RIII anti-PII serum) which was included on each 
plate.
Statistical analyses
Comparison of arthritis scores between groups was by 
Student’s unpaired t-test. Incidences and onset data 
were evaluated for significance of differences using a 
chi-square contingency table with alpha set at 95% 
confidence levels and one degree of freedom.
RESULTS
CIA among (BJO.RUlxRlUS)FJxparental strain  
progeny
We first analyzed (BlO.RIIIxRlIIS)FlxRIIIS and 
(BlO.RIIIxRIIIS)FlxBlO.RIII backcross mice for 
susceptibility to CIA induced by immunization with 
PII (Table 1). A higher total incidence and greater 
severity of arthritis occurred in the FlxBlO.RHI 
backcross mice (24/28; 85.7%;, 4 .1±2.0) compared to 
that of the FlxRIIIS backcross mice (8/27; 29.6%; 1.1 
±1.0). Thus, in these two populations of H-2r/r mice, 
greater susceptibility to CIA, based on incidence and 
severity, correlated with a greater concentration of 
non H-2 genes derived from the B10 parent. These 
second generation, H-2r/r backcross progeny are 
expected to segregate (1:1) into TCR genotypes of 
V f i b/c and V/?c/c among the FlxRIIIS progeny and 
TCR genotypes of V/JWc and V/Jb/b among the F ix  
B10.RIII progeny. Thus, clinical CIA correlated with 
the predicted greater frequency of the TCR V/Jb geno­
type among the FlxBlO.RIII backcross mice. Also, 
arthritic mice of both progeny groups showed a 
delayed onset time and less severe arthritis than the 
B10.RIII parental strain which is 100% B10 back­
ground and homozygous wild type TCR V/Jb/b.
Sex differences in CIA
To analyze for gender differences in CIA suscepti­
bility, arthritic male and female (BlO.RIIIxRIIIS)x 
B10.RIII mice were scored over a 4 month period 
using a detailed scoring system16 which provides a 
finer distinction between degrees of arthritis severity 
(Figure 1). Male mice of this genotype showed a more 
rapid onset and more severe arthritis than female lit- 
termates. The arthritis was prolonged, lasting for up to 
120 d. A mild, spontaneous exacerbation of joint 
inflammation also occurred in the male mice. A lim­
ited number of (BlOxRIIIS)Fl mice were tested and 
also showed a greater incidence of CIA in males (5/6) 
than in females (0/6).
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TCR genotypes and CIA in (B lO xR W S)F IxR /IIS  
progeny
We next determined the degree of susceptibility to 
PII-CIA among (B 10xRIIIS)FlxRIIIS progeny. Each 
mouse was analyzed individually for H-2 haplotype 
(r/r or r/b) by serotyping and for TCR V/J genotype 
(V/?b/b or VP b/c) by FACS analysis for TCR V/?8+ and 
TCR V/J6+ T cells in peripheral blood. A summary of 
eight different genetic groups comprising 137 F ix  
RIIIS offspring is presented in Table 2. Within each 
group that was identified among the (B 10xRIIIS)Flx 
RIIIS offspring (based on sex, H-2 haplotype and 
TCR alleles) the mean severity of arthritis (range
3.0-6.5) was substantially less than that of the 
BIO.RIII positive control mice (12±5) and the mean 
onset o f clinical arthritis was delayed by 2 to 4 weeks.
When the data are analyzed solely on the basis of 
TCR Vy3 genes (without regard to H-2 haplotype or 
sex), there was little difference in the incidence of 
CIA between TCR V ^ c/c mice (31/70; 45%) and TCR 
V/?b/c mice (44/67; 66%). Analysis of the data on the 
basis of sex and TCR haplotype revealed that only 
7/31 (23%) of the TCR V/Jc/c female mice developed 
CIA while the incidences of CIA among the TCR 
V/?c/c males, V/?b/c males, and V/?b/c females were sig­
nificantly higher (pS0.005), reaching 75% in the H- 
2r/b and TCR w p bk males. Hybrid H-2r/b class II mol­
ecules could potentially present novel collagen epi­
topes (i.e. ones not presented by H-2r/r class II 
molecules). Therefore, the comparison of CIA was 
restricted to H-2r/r mice. In this latter analysis, a hier­
archy of susceptibility was seen (based on incidences 
and severity respectively) that increased from 59% 
and 3.8 in TCR V/Jc/c male progeny, to 71% and 6.3 in 
their TCR Vfl**  male littermates and reaching to 
100% and 12.0 in TCR V 0 m  BIO.RIII mice. Like­
wise, the arthritis incidence and mean severity score
Figure 1 Comparison of severity of arthritis in male [ • - • ]  and 
female [O-O] (BlORIIIxRIIIS)FlxBlO.RIII mice after immuniz­
ation with porcine type II collagen. Data are from Table 1 and are 
group means+SD.
increased significantly from 23% and 3.0 in H-2r/r 
V/?c/c female hybrids to 59% and 4.4 in their V/Jb'= 
female siblings (p<0.005). Thus, in both male and 
female (B 10xRIIIS)FlxRIIIS hybrid progeny, TCR 
V/?b genes were associated with higher susceptibility 
to PII-CIA compared to their TCR V/?c/c sibs of the 
same sex and H-2 haplotype (Table 2).
FACS analysis showed that although the TCR het­
erozygous (V/Jb/c) mice exhibit the full complement of 
TCr V/? phenotypes, the concentration of circulating 
TCR V/28+ and V/J6+ T cells was approximately one- 
half that of TCR V/?b/b BIO.RIII control mice, as 
expected due to allelic exclusion. These results sug­
gest that the decreased CIA among the TCR V/Jb/c Fl 
xRIIIS hybrid mice (relative to CIA in BIO.RIII mice) 
might reflect a TCR dose-response phenomenon. 
Alternatively, other background genes of RIIIS origin, 
which would be segregating independently of the TCR 
loci among the FIxRIIIS offspring, could also be 
responsible for downregulation of joint inflammation 
in these mice.
PII-CIA in RIIIS mice
Because of the mild PII-CIA in the (B 10xRlIlS)Flx 
RIIIS progeny carrying the RIIIS TCR deletion, we 
tested inbred RIIIS mice for susceptibility to PII-CIA. 
The induction protocol was changed so as to use CFA 
in the booster injections at 21 d. A total of 50 RIIIS 
mice, ages 2 -4  months, were initially tested for sus­
ceptibility to PII-CIA and level o f anti-Mil serum 
antibody (Table 3). The incidence among RIIIS males 
(50%) was significantly higher (p>0.02) than that of 
RIIIS females (12.5%). Both male and female R111S 
mice showed a delayed onset and less severe arthritis 
than the BIO.RIII control mice (p<0.001). These 
results are equivalent to and thus confirm the data 
obtained with the (B 10xRIIIS)FlxRIIIS hybrids 
shown in Table 2. PII-CIA did develop in RIIIS (H- 
2r/r, V P ^ )  mice but in the absence of the wild-type 
TCR V/?b/b genome the joint inflammation was very 
mild, delayed in onset, substantially decreased in inci­
dence and occurred predominantly in males.
In an extension of this study of PII-CIA to a total of 
83 RIIIS mice, we subsequently have not detected an 
effect of age on either the incidence (20-50%) or 
severity (scores 2.4-3.6) o f CIA in the RIIIS male 
mice (Table 4). However, we did note a trend towards 
increasing incidences of CIA in older RIIIS female 
mice. Only 2/19 (11%) of RIIIS females that were 
immunized between 2 and 4 months of age developed 
PII-CIA versus 8/16 (50%) of RIIIS females immun­
ized at 6 -10  months of age (p<0.02). However, the 
greatest differences in response to challenge with Pll 
remained to be between RIIIS mice of either sex and 
companion BIO.RIII positive control mice which rou-
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Table 3 Summary of CIA in RIIIS mice immunized with porcine type II collagen
Mice Arthritis*
Serum IgG Anti-Collagen 
28 days
Antibody Levels (Units/ml) 
100 days




p n Mil PII Mil
RIIIS M 13/26(50%) 59±21 4.0±1.6 42±21 138±68 278±172 121±81
RIIIS F 3/24 (13%) 7I±I 3.5±0.7 40+33 I21±78 206+131 80±74
BlO.RIII M 9/9 (100%) 39+11 13.3±0.5 100 100 ND ND
•MeanstS.D, arthritic mice only. IgG anti-MII and anti-PIl were by ELISA. Antibody units/ml by a standard curve from a pooled, BEO.RIII anti-Pil control sera assigned an arbitrary value 
of 100 Ab, Units/ml. RIIIS males were significantly different from RIIIS females (p<O.0O5) in incidence and from male B I0.RIII mice in incidence and severity (p<0.0l).
Table 4 Age al time of immunization (2-10 months) and PII-CIA 
among RIIIS male and female mice
Age* Males Females
Incidence Severity Incidence Severity
30-40 7/11 (64%) 2.4±1.3 4/7 (57%) 5.4±1.7
23-27 7/23 (54%) 2.9±1.8 4/9 (44%) 2.8± 1.3
13-18 10/17 (59%) 3.6± 1.8 2/12 (17%) 2.5±2.1
7 3/7 (43%) 3.0±0.6 0/7 (0%) —
»Age in weeks at primary immunization wilh PII. Data arc Means±S.D o f arthritic mice 
only. Male BlO.RIII mice used as positive control mice developed CIA in 100% incidence 
with mean severity scores o f  >13.
tinely developed PII-CIA in >90% incidence and 
severity scores of >13 during this study (p<0.005).
Clinically, CIA in the RIIIS mouse differs from that 
of'BlO .R III control mice. Joint inflammation in 
B 10.RIII mice with CIA is severe, involving the entire 
paw, which is grossly swollen, including ankles, toes 
and mid-foot and routinely leads to cartilage destruc­
tion and ankylosis. In RIIIS mice with CIA, arthritis is 
mild, is commonly restricted to only one or two joints, 
lacks the edema that is characteristic o f  BlO.RIII 
mice, and rarely results in ankylosis of the joint.
Immune response to PII and M il  in BlO.RIII and RIIIS
mice
The level o f serum IgG anti-MII and anti-PII antibody 
was measured at 28 and 100 d after primary immuniz­
ation (Table 3). At 28 d, the levels of anti-PII and 
anti-MII antibody in RIIIS mice were high and equiv­
alent to that of B 10.RIII (Table 3). At 100 d, a further 
increase in anti-PII antibody titers was detected while 
anti-MII antibody was stable or somewhat decreased 
at this later time point. We also confirmed previous 
reports that the mate RIIIS mouse is not complement 
deficient (data not shown) by a standard hemolysis 
assay as previously described19. At 28 d, there was a 
trend towards higher anti-MII antibody levels in 
arthritic male RIIIS mice (158+65 Ab U/ml) com­
pared to non-arthritic male RIIIS mice (116+69) and 
non-arthritic female RIIIS mice (109±75). Likewise, 
at 28 d anti-PII antibody levels were higher in arthritic 
male RIIIS mice (140±93) compared to non-arthritic 
male (99+63) and non-arthritic female (79+75) RIIIS
mice. However, the broad range of responses that was 
obtained rendered these differences statistically non­
significant.
DISCUSSION
Studies with the CIA model of autoimmunity in mice 
and rats have demonstrated that the joint destruction 
associated with collagen autoimmunity can be down- 
regulated by inhibiting the formation of the tri-mol- 
ecular complex— [class II antigen presenting mol­
ecule, collagen epitope, collagen-specific TCR 
molecule]— which is instrumental in the initiation 
and promulgation of anti-collagen immune 
responses6,8'18 '9. Because of the exciting new treat­
ment modalities for human autoimmune disease that 
are suggested by these findings, and in order to cor­
rectly test the efficacy of potentially immunomodulat- 
ing peptides in this model, it is important to define the 
number and variety of TCR molecules and collagen 
epitopes that can interact to produce pathological col­
lagen autoimmunity.
Attempts to identify the specific TCRs involved in 
murine CIA have produced conflicting reports9 '1,20-27. 
Most investigations have focused on TCR V/J utiliz­
ation in CIA and have been performed in the H-2q 
mice DBA/1 and SWR after immunization with bov­
ine (BII) or chick (CII) collagen. SWR lacks TCR 
genes encoding the V/J5, V/J8, V/39, V/J11, V/J12, 
and V/?13 families (Vy3“) but, in contrast to RIIIS, 
retains V/J6, V/J15 and V/J17 genes28. Early gene seg­
regation studies implicated both V/J8+ and V/J6+ T 
cells in CIA induced by BII in second generation, H- 
2q/b mice originating from BlOxSWR matings'1,20. 
Others subsequently reported that CIA in (DBA/1 x 
SWR)F2 progeny immunized with CII can be driven 
by T cells expressing TCRs with V/J domains encoded 
outside of the SWR deletion region, but the identity of 
the TCRs was not addressed2'. Chiocchia et a l.22 found 
that elimination of TCR Vj38.1,2+ or V/J5.1,2+ plus 
VJ32+ T-cells by administration of V/J-specific mono­
clonal antibody protected DBA/1 mice from B1I-CIA. 
Recently, in a unique approach, Mori et a l ?  isolated 
the TCR WB chain gene from a Cll-reactive T cell
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clone and used transgenic mouse technology to sug­
gest a contributing, but not primary, role for V/312+ 
TCRs in the CIA of (SW R xD BA /l)Fl hybrids. Also, 
Moder et al.25 used monoclonal antibody therapy to 
show that DBA/1 mice do not absolutely require V/? 
8+ T cells for CIA.
A divergence of results is expected among in vivo 
studies in which collagens of different species (BII, 
CII, PII) are used to induce CIA in mice of different 
H-2 haplotypes. This is because of the multiple, 
species-specific differences in the immunogenic epi­
topes of type II collagen that are variably recognized 
by allelic class II and TCR molecules29-32. In mice 
lacking T cells expressing TCR molecules of major 
importance in CIA due to genomic or clonal deletions, 
then T cells bearing alternative or minor TCR mol­
ecules may drive the disease in a mild form. Further­
more, different TCR molecules may be involved at 
different stages of the disease, perhaps in the gener­
ation of autoimmunity specific for mouse collagen 
peptides or other cartilage autoantigens that are 
released into the joint space during active arthritis. 
Also, in some strains, the functions of background 
genes (non-H-2 and non-TCR) may mask the primary 
levels of control extant at the class II, peptide and 
TCR interaction stage of immune initiation.
Few studies have addressed the TCR V/? usage of 
other CIA positive H-2 haplotypes such as H-2r mice 
nor has PII (which is a poor arthritogen for H-2q mice) 
been used. Recently, Moder et at.25 demonstrated that 
depletion of circulating V/38+ T cells by adminis­
tration of F23.J, a monoclonal antibody specific for 
members of the V/?8+ family of TCR molecules, 
resulted in a significant inhibition of arthritis in PII- 
immunized B10.RI1I mice, thus directly establishing 
that V/38+ T cells are also involved in the generation 
of PII-CIA in the B10.RIII strain. The data in the cur­
rent report demonstrate that in the absence of V/?8+ T 
cells, because of genomic deletions, mild PII-CIA can 
be driven in H-2r/r mice by a less pathogenic subset of 
T-cells expressing one or more alternative TCR mol­
ecules that are encoded outside of the deletion region 
of RIIIS mice. Similarly, even after depletion of circu­
lating V/J8+ T cells with the F23.1 monoclonal anti­
body, mild arthritis develops in a low percentage of 
Pll-immunized B10.RIII mice25, again suggesting the 
participation of a second PH-reactive T cell. The data 
reported herein confirm that the induction of severe 
arthritis of rapid onset in H-2r mice by immunization 
with PII coincides with the availability of circulating 
T cells bearing TCRs that are encoded within the gen­
omic deletion region of RIIIS, and thus supports the 
hypothesis of a primary association of CIA in PII- 
immune, B10.RIII mice with T cells expressing V/38+ 
TCRs.
RIIIS mice likely differ from B10.RIII mice at 
additional (non-TCR) loci, the products of which
could also affect the clinical expression of CIA in 
these mice. Of potential importance are the genes 
which encode the numerous immunoregulatorv 
mediators and their cell surface receptor molecules 
For example, SWR mice are genetically deficient in 
the complement component C5a and this defect has 
been proposed as a major factor in the CIA resistance 
of this strain of mice21,33,34; however, others have 
reported conflicting findings when a different exper­
imental approach was adopted24. During the course of 
this study we confirmed that RIIIS male mice are not 
complement deficient but other immunomodulating 
molecules, such as the interleukins, tumor necrosis 
factor, interferon gamma, were not addressed.
A sex difference in CIA susceptibility has pre­
viously been reported in DBA/1 mice when immun­
ized with homologous mouse type II collagen35,36. In 
this paper, we show a preponderance of disease in 
young RIIIS males and in (BlO.RIIIxRIIIS)Flx 
B10.RIII males. One explanation for this sex-bias in 
murine CIA may be that if mice develop only a rela­
tively low level o f cellular anti-MII autoimmunity, 
other components of the immune/inflammatory- 
response milieu may become rate-limiting and thus 
down-regulate clinical expression of autoimmune 
arthritis. Potential sex-linked regulators of CIA are 
complement components2' 34, female sex hor­
mones35,36, and the adrenal corticosteroids, which 
modulate disease in other models of autoimmunity 
and arthritis in rats37. These factors may become clini­
cally important in specific mice in which the auto­
immune reactivity to collagen is low or is of an incor­
rect immunoglobulin class, sub-class, or epitope 
specificity.
The very high level of anti-PII and anti-MII anti­
body in RIIIS mice, was initially surprising in view of 
the very mild clinical arthritis that was exhibited by 
these mice. Similarly high anti-MII antibody levels 
occur in the SWR mouse, another TCR deletion 
mutant, V /?^, but are difficult to equate with the 
results of the present study because the SWR mouse is 
complement deficient whilei the RIIIS mouse is 
not38,39. Also, there was no strong correlation between 
anti-MII titers and joint involvement within the total 
population of male RIIIS mice. We are currently ana­
lyzing these sera for disease-related differences in iso­
type or epitope specificity.
We propose two explanations for the current obser­
vations which are not mutally exclusive. First, IgG 
anti-MII antibodies with strong arthritogenic potential 
(i.e. correct epitope specificity and sub-class identity) 
may be produced preferentially when the immune sys­
tem is driven by T-cells expressing V/38+ TCRs, 
which are present in B10.RIII mice but not RIIIS 
mice. Thus, RIIIS mice may produce high levels of 
anti-collagen antibodies that are pathologically benign 
compared to those of B10.RIII mice. Alternatively,
TCR USAGE OF H-2r MICE WITH CIA 227
the synovial cell activation, monocyte recruitment, 
pannus formation and subsequent cartilage and joint 
destruction that characterizes the severe arthritis of 
pll-immune BIO.RIII mice may require the active par­
ticipation and local cytokine production of collagen- 
specific, Thl effector cells. Collagen-reactive, Thl 
cells may express TCRs which preferentially incor­
porate V/3 chains normally encoded within the RIIIS 
deletion region, at least one of which is proposed to be 
ofthe V/38 family. In the RIIIS mouse, collagen reac­
tive T cells (which perforce must utilize TCR V/3 mol­
ecules other than V/38) may be predominantly of the 
Th-2 type which could drive antibody production but 
would not efficiently activate resident joint cells 
because of a different cytokine profile40. Thus, CIA in 
Pll-immunized RIIIS mice may represent a predomi­
nantly antibody driven disease while the more severe 
PII-CIA in BIO.RIII mice may reflect the added 
effects of inflammatory cytokines produced in the 
joint by collagen reactive Th-1 cells. We are currently 
carrying out a detailed comparison of the immuno­
biology of PII-CIA in the BIO.RIII and RIIIS mouse 
strains to resolve these questions.
There is now convincing evidence that specific 
TCR-bearing T cell substrates can be either selec­
tively expanded or clonally deleted in the peripheral 
circulation by interaction with certain products of 
several common microorganisms and endogenous 
retroviruses that are collectively termed “super­
antigens”41. Superantigens bind to the V/3 chains of 
TCR molecules outside of the peptide groove and thus 
are TCR-specific but are not antigen-specific. These 
findings suggest a mechanism whereby exposure to 
particular infectious agents could cause proliferation 
of auto-reactive T cell clones and thereby precipitate 
autoimmune disease in genetically susceptible indi­
viduals41-43. If this etiologic relationship is to be pro­
posed, it is necessary to demonstrate commonality 
between TCRs involved in disease-related auto­
immunity and the TCRs that bind to candidate super­
antigens.
Mls-T' is an endogenous retroviral superantigen 
(Mtv-7) that is found in certain strains of mice44. TCR 
molecules that are M ls-la reactive have been associ­
ated with several murine models of autoimmune 
arthritis. Anderson et a l .16 showed that clonal deletion 
of M ls-la reactive T-cells decreased the incidence of 
CH-induced CIA in BlO.QxBALB/c (H-2q/d) mice. 
Also, Haqqi et a l .21 analyzed cells isolated from the 
arthritic joints and draining lymph nodes of CII- 
immunized B10.Q mice by polymerase chain reaction 
technology. RNA transcripts of only a few TCR V/3 
genes were found, predominantly V/36, V/38.2 and less 
frequently V/39 and V/J7, indicating that T cells bear­
ing these particular TCR molecules were driving the 
joint inflammation of these arthritic mice. M ls-la 
reactive T cells are also active in both the pristane-
induced and proteoglycan-induced models of arthritis 
in mice4546. It is noteworthy that V/35+ T cells were 
recently implicated in CIA of H-2q mice22; V/35+ and 
V/311+ T cells are clonally deleted in mice such as 
BIO.RIII that carry a second retroviral integrant, Mtv-
9, and also express H-2E class II antigen presentation 
molecules47. Of the TCR V/3 chains reactive with Mtv- 
7 (V/36, V/37, V/38.1, V/39) and Mtv-9 (V/35, V/311) 
only V/37 is outside of the RIIIS deletion region.
A superantigen produced by M ycoplasma arthrit­
idis  (MAM) has been found to interact with a group of 
mouse TCR molecules, some of which are also Mtv-7 
and Mtv-9 reactive48,49. In a previous analysis of 
MAM-reactive T cells in rats, we determined that sus­
ceptibility to BH-induced CIA and T-cell reactivity to 
MAM are co-inherited in the F2 and F lxB N  
backcross progeny of DA (R T lavl, CIA-susceptible, 
MAM responder) and BN (R T ln, CIA-resistant, MAM 
non-responder) mating pairs50. Subsequently, careful 
analysis of the murine TCRs reactive with MAM have 
shown a heirachy of responder types. TCRs that are 
V/38.1+, 8.2+, 8.3+, 5.1+ or 6+ (which are within the 
RIIIS deletion region) are very strongly reactive with 
MAM49,51; a much weaker MAM reactivity to one or 
more V/3 chains encoded outside of the RIIIS deletion 
region can be detected in the RIIIS mouse by in vitro  
stimulation of spleen and node lymphocytes with high 
concentrations of MAM (BC Cole, AN Theofilo- 
poulos, unpublished observations). Our current study 
shows a clinically mild CIA response in RIIIS mice 
that possess a TCR repertoire that is restricted to V/3 
chains encoded outside of the V/F deletion region. 
Studies are now ongoing to determine if these alterna­
tive TCR molecule(s) involved in PII-CIA in the 
RIIIS mouse are also reactive with superantigens such 
as MAM and Mis.
These similarities in TCR utilization in response to 
MAM, retroviral gene products, and type II collagen 
among rodents may be fortuitous. Also, as discussed, 
clinical arthritis can be modulated by any of several 
different, nonspecific mediators of inflammation. 
However, the combined data provide suggestive evi­
dence that type II collagen, certain retroviral gene 
products, and MAM may interact with a related group 
of TCR molecules. This concordance of TCR utiliz­
ation is noteworthy, suggesting an underlying and 
fundamental relationship betwen superantigens and 
autoimmune arthritis which may or may not be causal 
in nature. Regardless, the potential for gaining an 
increased understanding of the respective and inter­
active roles of superantigens derived from environ­
mentally acquired infectious agents and the genetic 
predisposition to autoimmune disease unique to each 
host is strong enough to warrant further investigation. 
This is particularly true in the context that activated T 
cells bearing the human equivalent of murine V/36+, 
V/37+ and V/38+ (Human V/3l7(19), V/33, V/314) have
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recently been identified in the synovial tissues of 
patients with rheumatoid arthritis52 and that type II 
collagen is a major autoantigen in patients with rheu­
matic disease.
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